THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...
Repatha (evolocumab) isn’t known to interact with other medications, supplements, herbs, vitamins, vaccines, or lab tests. There are no known direct interactions between Repatha and alcohol. However, ...
A series of abstracts also made the case for serious gaps in GLP-1 treatment, which Amgen figures its investigational MariTide could fill. (Amgen, American Diabetes Association) As Amgen strives to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results